Angiotech/Baxter
This article was originally published in The Gray Sheet
Executive Summary
Manufacturing rights for Angiotech's CoSeal surgical sealant and Adhibit surgical anti-adhesive products are granted to Baxter under an April 21 agreement. The pact expands on the firms' Feb. 25 alliance giving Baxter exclusive worldwide distribution rights, except for Japan (1"The Gray Sheet" March 3, 2003, In Brief)...
You may also be interested in...
Baxter CoSeal licensing PMA
Regulatory responsibility for surgical sealant transfers to Baxter with approval. The submission required no data or inspections. Baxter licensed CoSeal manufacturing rights from Angiotech Pharmaceuticals in April (1"The Gray Sheet" April 28, 2003, In Brief)...
Baxter/Angiotech CoSeal
Surgical sealant and Adhibit surgical anti-adhesive product will be marketed by Baxter under a worldwide (excluding Japan) strategic alliance announced Feb. 25. Angiotech expects an upfront fee of $8 mil., further payments of up to $14.7 mil., and a percentage of sales "in the low double digits." The Canadian firm completed its roughly $42 mil. acquisition of product developer Cohesion Technologies in February (1"The Gray Sheet" Feb. 24, 2003, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”